Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARBOR: Del-desiran in Myotonic Dystrophy Type 1
NCT06411288Phase 3Completed
- Sponsor
- Avidity Biosciences
- Start
- May 2024
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Conjugated siRNA, Peptide-Drug Conjugates
- Countries
- 10
01
Overview
A Phase 3 trial of delpacibart etedesiran in myotonic dystrophy type 1 (DM1), sponsored by Avidity Biosciences. Started May 2024; status: completed.
02
Drugs
delpacibart etedesiran
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT06411288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411288.